Konruns(SH:603590) Zheng Quan Zhi Xing·2025-07-11 16:25Core Viewpoint - Beijing Kangchen Pharmaceutical Co., Ltd. experienced a significant stock price fluctuation, with a cumulative closing price deviation exceeding 20% over three consecutive trading days from July 9 to July 11, 2025, indicating abnormal trading activity [1][2]. Group 1: Stock Trading Abnormalities - The company's stock price increased significantly, with a cumulative closing price deviation exceeding 20% over three consecutive trading days [1]. - The company conducted a self-examination and confirmed that there were no undisclosed significant information related to the stock price fluctuations [2]. Group 2: Business Operations - The company's production and operational activities are reported to be normal, with no significant changes in daily operations [1]. - There are no major undisclosed events such as asset restructuring, stock issuance, or significant business collaborations that could impact the stock price [2]. Group 3: Sensitive Information - During the period of stock price fluctuation, company executives and major shareholders did not engage in buying or selling the company's stock [2]. - The company holds a 4.96% stake in Nuance Biotech and has exclusive rights for the clinical development and commercialization of Ensifentrine in Greater China, valued at approximately $10 billion [2].